Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
J Virol ; 82(20): 10188-98, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18667506

ABSTRACT

The infectious cycle of human cytomegalovirus (HCMV) is intricately linked to the host's cell cycle. Viral gene expression can be initiated only in G(0)/G(1) phase. Once expressed, the immediate-early gene product IE2 prevents cellular DNA synthesis, arresting infected cells with a G(1) DNA content. This function is required for efficient viral replication in vitro. A prerequisite for addressing its in vivo relevance is the characterization of cell cycle-regulatory activities of CMV species for which animal models have been established. Here, we show that murine CMV (MCMV), like HCMV, has a strong antiproliferative capacity and arrests cells in G(1). Unexpectedly, and in contrast to HCMV, MCMV can also block cells that have passed through S phase by arresting them in G(2). Moreover, MCMV can also replicate in G(2) cells. This is made possible by the cell cycle-independent expression of MCMV immediate-early genes. Transfection experiments show that of several MCMV candidate genes, only immediate-early gene 3 (ie3), the homologue of HCMV IE2, exhibits cell cycle arrest activity. Accordingly, an MCMV ie3 deletion mutant has lost the ability to arrest cells in either G(1) or G(2). Thus, despite interspecies variations in the cell cycle dependence of viral gene expression, the central theme of HCMV IE2-induced cell cycle arrest is conserved in the murine counterpart, raising the possibility of studying its physiological relevance at the level of the whole organism.


Subject(s)
G1 Phase/physiology , G2 Phase/physiology , Gene Expression Regulation, Viral , Genes, Immediate-Early/genetics , Muromegalovirus/genetics , Muromegalovirus/physiology , Animals , Cell Proliferation , DNA Replication , Humans , Immediate-Early Proteins/genetics , Immediate-Early Proteins/metabolism , Mice , Muromegalovirus/pathogenicity , NIH 3T3 Cells , Trans-Activators/genetics , Trans-Activators/metabolism
2.
J Clin Endocrinol Metab ; 92(3): 1041-8, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17192291

ABSTRACT

BACKGROUND: Obesity is a major risk factor for breast cancer. We hypothesized that obesity-induced decreases in total and/or high-molecular-weight (HMW) adiponectin levels may underlie this association. METHODS: We measured serum total and HMW adiponectin in a hospital-based case-control study of 74 female breast cancer patients and 76 controls. In parallel, expression of adiponectin and its receptors AdipoR1/R2 were measured in tissue samples using RT-PCR, and protein expression of AdipoR1/R2 was localized and quantified using immunohistochemistry. Finally, we documented AdipoR1/R2 expression in several breast cancer cell lines and studied adiponectin signaling and the effect of adiponectin on proliferation in the T47D breast cancer cell line in vitro. RESULTS: Women with the highest adiponectin levels had a 65% reduced risk of breast cancer (P = 0.04). This association became stronger after adjustment for age, body mass index, and hormonal and reproductive factors (P = 0.02). Modeling HMW instead of total adiponectin produced similar results and did not offer any additional predictive value. Breast cancer cells expressed AdipoR1/R2 but not adiponectin. Expression of AdipoR1, but not AdipoR2, was higher in tumor tissue than both adjacent and control tissues. Exposure of T47D cells to adiponectin significantly inhibited the percentage of viable cells to 86% and proliferation to 66% but had no effect on apoptosis. These effects were associated with activation of ERK1/2 but not AMP-activated protein kinase or p38MAPK. CONCLUSION: These studies suggest that adiponectin may act as a biomarker of carcinogenesis and may constitute a molecular link between obesity and breast cancer.


Subject(s)
Breast Neoplasms/blood , Carcinoma/blood , Adiponectin/blood , Adiponectin/chemistry , Adiponectin/metabolism , Adiponectin/pharmacology , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Carcinoma/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Humans , Middle Aged , Molecular Weight , Receptors, Adiponectin , Receptors, Cell Surface/metabolism , Tissue Distribution
3.
Am J Clin Nutr ; 86(3): s858-66, 2007 09.
Article in English | MEDLINE | ID: mdl-18265479

ABSTRACT

Adiponectin, an adipocyte-secreted hormone that plays an important role in diabetes and cardiovascular disease, may also be of importance in the development and progression of several malignancies. Circulating adiponectin concentrations, which are determined mainly by genetic factors, nutrition, and adiposity, are lower in patients with breast, endometrial, prostate, and colon cancer. It has thus been proposed that adiponectin may be a biological link between obesity (especially central obesity) and increased cancer risk. Adiponectin may influence cancer risk through its well-recognized effects on insulin resistance, but it is also plausible that adiponectin acts on tumor cells directly. Several cancer cell types express adiponectin receptors that may mediate the effects of adiponectin on cellular proliferation. Herein, we review recent evidence supporting a role of serum adiponectin concentrations as a novel risk factor and possible diagnostic marker for obesity-related malignancies, including cancers of the breast, endometrium, colon, and prostate. Further studies are needed to fully elucidate the potential role of adiponectin in cancer diagnostics and therapeutics.


Subject(s)
Adiponectin/physiology , Insulin Resistance , Neoplasms/etiology , Obesity/metabolism , Adiponectin/blood , Adiponectin/metabolism , Biomarkers, Tumor/blood , Cell Division/drug effects , Cell Proliferation/drug effects , Cell Transformation, Neoplastic/drug effects , Female , Humans , Insulin/blood , Male , Neoplasms/metabolism , Receptors, Adiponectin/metabolism , Risk Factors , Signal Transduction
4.
Z Arztl Fortbild Qualitatssich ; 97(4-5): 339-41, 2003 Jul.
Article in German | MEDLINE | ID: mdl-12891979

ABSTRACT

Integrating a problem-based learning (PBL) approach into the classical curriculum for medical students is often considered difficult because of fundamental differences in the two teaching methods. At the Charité, the medical school of Berlin's Humboldt University, students with a regular medical curriculum are offered to choose between a regular and a PBL class for their course in Paediatrics. During the three-week course in PBL Paediatrics medical students spend the morning in different clinics of the "Otto Heubner Centre for Paediatrics". They are strongly involved in the medical care of 3-4 patients with typical paediatric diseases. Each afternoon, one of the students presents a patient. Patient problems are discussed according to the seven steps of PBL. Subsequently, students use different tools and sources through self-studies to obtain information on the specific disease. By integrating the principles of "Evidence-based medicine" students are trained to critically appraise the medical literature. At the end of the course students are asked to evaluate the quality of the medical teacher, thus allowing for continuous improvement of the teaching methods. We conclude that the principles of PBL can be integrated into a conventional curriculum in medical school.


Subject(s)
Pediatrics/standards , Problem-Based Learning/methods , Berlin , Child , Curriculum , Hospitals, University/standards , Humans , Pediatrics/education , Problem-Based Learning/standards , Quality Assurance, Health Care , Schools, Medical/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...